ARTICLES BY LOUIS

• A Biotech Outsourcing For Sickle Cell Anemia

  12/16/2021

  CEOs are excellent communicators - so good, they easily slide into a bit of over-promotion. With Rahul Ballal, CEO, Imara, Inc., you get the clear communication without the ballyhoo. That’s why his tale of an incubator-bred biotech, its small-molecule program for sickle cell anemia, and outsourcing strategy, is so relatable. 

• Inflation Bites Biopharma In The Outsourcing Budget

  12/13/2021

  “I don't see how prices come down when they won't need to. Demand for outsourcing services is not going away.” “Suddenly a year from now you're going to get people to take a lower salary to do the same job?” Here's the real inflation bite at biopharma.

• Inflation Fears: Supply-Chain Lessons From Past Periods In US, And USSR

  12/1/2021

  I’m old enough to be concerned with inflation in the US because of direct experience in the '70s. Experience was also Vadim Klyushnichenko's starting point for a discussion on today’s inflation. His experience was in Russia in the '90s. Perhaps both he and I are overreacting? You be the judge.

• How Inflation Deflates Domestic Outsourcing

  11/23/2021

  Rising inflation in the U.S. is a major worry for biopharma CEOs who – as most all of them do – rely on outsourcing drug development and manufacturing. But what politicians and others are trying to enact here is not going to accomplish what they want – lower drug prices. And it's not helping U.S.-based CDMOs.

• Why Do We Outsource To China?

  11/18/2021

  We do so because many CDMOs there provide excellent drug/therapy development and manufacturing services, pricing is lower, available skilled workforce, etc. But we are also propelled there by circumstances created by political policy and societal fiat.

• Inflation Sticks, Supply Chains Stall, Outsourcing A Struggle

  11/17/2021

  Year two of COVID closes precariously as we face multiplying supply-chain challenges, and mounting inflation. What of drug development and manufacturing outsourcing specifically? I asked executives how much these two factors are affecting projects, particularly related to working with CDMOs.

• Small Acquisition Leads To Critical Analysis Of Outsourcing

  11/12/2021

  Here’s how a relatively simple acquisition announcement in a corner of our biotech industry led us to a multifaceted analysis of global drug development and manufacturing outsourcing. (Part 1)

• Big-Bio Pro Tackles Outsourcing For Emerging Biopharma

  11/8/2021

  After 20 years, Tom Holmes was leaving Biogen. He’d take his time deciding what came next. I was surprised by his final choice. He hitched his career to Amylyx, a company combining well-known small-molecules as a new drug for amyotrophic lateral sclerosis (ALS). He thinks others should make similar career changes

• Can Biomanufacturing Support U.S. Cities?

  11/1/2021

  Are big cities in the U.S. amenable to biomanufacuting operations? Are they great places to live and work? I have some doubts. In a recent discussion, [Joseph Fetterman](https://www.colliers.com/en/experts/joseph-fetterman), Executive Vice President, Colliers Life Sciences, tried to disabuse me of them. He has the blueprint to demonstrate his optimism. 

• $10 Billion And 1 Million Liters: Here Comes The Biomanufacturing Capacity!

  10/28/2021

  Remember when a lack of capacity was going to feel like a massive concrete slab blocking the road to a biopharmaceutical revolution? Instead, it's felt like so many bricks placed in the paths of individual drug development programs. Now CDMOs are building to meet demand. Is it the right kind of capacity?